hSSB2 activator / BCN Biosci - LARVOL DELTA

First in class hSSB2 activator as a dual therapeutic strategy for overcoming RAS/MAPK inhibitor resistance while protecting normal epithelia in aggressive cancers (AACR 2026) - "Mice were randomized to four arms: vehicle control, BCN077 monotherapy, standard FOLFOX plus Encorafenib (Braftovi®) and cetuximab, or the same triplet regimen combined with BCN077...Lastly, in vivo data clearly indicate that BCN077 has profound protective effects from cytotoxic therapy employed in cancer treatment such as radiation. hSSB2 is a novel target and holds great promise for use in cancer therapy, in particular where there is resistance to targeted therapeutics in the MAPK pathway such as RAS, BRAF, MEK inhibitors where resistance enables cell cycle checkpoint evasion."

Late-breaking abstract • Colorectal Cancer • Oncology • Solid Tumor • BUB1